School of Chemical & Biotechnology, SASTRA Deemed University, Thanjavur, India; Centre for Nanotechnology & Advanced Biomaterials, SASTRA Deemed University, Thanjavur, India.
School of Chemical & Biotechnology, SASTRA Deemed University, Thanjavur, India; Centre for Nanotechnology & Advanced Biomaterials, SASTRA Deemed University, Thanjavur, India; School of Arts, Sciences, Humanities & Education, SASTRA Deemed University, Thanjavur, India.
Eur J Pharmacol. 2024 Oct 15;981:176872. doi: 10.1016/j.ejphar.2024.176872. Epub 2024 Aug 6.
Alzheimer's disease is a neurodegenerative disorder that affects elderly, and its incidence is continuously increasing across the globe. Unfortunately, despite decades of research, a complete cure for Alzheimer's disease continues to elude us. The current medications are mainly symptomatic and slow the disease progression but do not result in reversal of all disease pathologies. The growing body of knowledge on the factors responsible for the onset and progression of the disease has resulted in the identification of new targets that could be targeted for treatment of Alzheimer's disease. This has opened new vistas for treatment of Alzheimer's disease that have moved away from chemotherapeutic agents modulating a single target to biologics and combinations that acted on multiple targets thereby offering better therapeutic outcomes. This review discusses the emerging directions in therapeutic interventions against Alzheimer's disease highlighting their merits that promise to change the treatment paradigm and challenges that limit their clinical translation.
阿尔茨海默病是一种影响老年人的神经退行性疾病,其发病率在全球范围内持续上升。不幸的是,尽管经过几十年的研究,我们仍然无法完全治愈阿尔茨海默病。目前的药物主要是对症治疗,可减缓疾病进展,但不能逆转所有疾病病理。对导致疾病发生和进展的因素的认识不断增加,已确定了新的治疗靶点,可用于治疗阿尔茨海默病。这为阿尔茨海默病的治疗开辟了新的前景,治疗方法已从调节单一靶点的化疗药物转向针对多个靶点的生物制剂和联合用药,从而提供更好的治疗效果。本文讨论了针对阿尔茨海默病的治疗干预的新兴方向,强调了它们有望改变治疗模式的优点,以及限制其临床转化的挑战。